Known targets — ChEMBL curated mechanism
POLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PRIM1PRIM2
The experimentally established mechanism targets of Troxacitabine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 known ✓ | P09884 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.60 |
| ▸ | ALB | P02768 | 3/20 | 0.60 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.60 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.60 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.60 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | MTOR | P42345 | 1/20 | 0.53 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.53 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.53 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.50 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.50 |
| ▸ | POLG | P54098 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
| ▸ | NT5E | P21589 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Troxacitabine SCHEMBL1026150 | 1.00 | LMNA (0.60) | LMNAPDE3AALBCACNA1FMAPT | |
| Troxacitabine SCHEMBL18548 | 1.00 | LMNA (0.60) | LMNAPDE3AALBCACNA1FMAPT | |
| Troxacitabine SCHEMBL1026148 | 1.00 | LMNA (0.60) | LMNAPDE3AALBCACNA1FMAPT | |
| Troxacitabine SCHEMBL1653267 | 1.00 | LMNA (0.60) | LMNAPDE3AALBCACNA1FMAPT | |
| Troxacitabine SCHEMBL6424800 | 1.00 | LMNA (0.60) | LMNAPDE3AALBCACNA1FMAPT | |
| Troxacitabine SCHEMBL30317744 | 1.00 | LMNA (0.60) | LMNAPDE3AALBCACNA1FMAPT | |
| Troxacitabine SCHEMBL22285889 | 0.99 | LMNA (0.59) | LMNAPDE3AALBCACNA1FMAPT | |
| Troxacitabine SCHEMBL17542009 | 0.95 | LMNA (0.56) | LMNAPDE3AALBCACNA1FMAPT | |
| Troxacitabine SCHEMBL7560355 | 0.89 | POLG (0.59) | LMNAPDE3AALBCACNA1FMAPT | |
| SCHEMBL31347648 | 0.88 | LMNA (0.59) | LMNAPDE3AALBCACNA1FMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070259832-A1 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2007-11-08 | — | — | US | claimed |
| EP-1485395-A2 | NUCLEOTIDE MIMICS AND THEIR PRODRUGS | Biota, Inc. (US) | 2004-12-15 | — | — | EP | claimed |
| WO-2003072757-A9 | NUCLEOTIDE MIMICS AND THEIR PRODRUGS | BIOTA INC (US) | 2004-10-21 | — | — | WO | claimed |
| US-20040059104-A1 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2004-03-25 | — | — | US | claimed |
| WO-2003072757-A2 | NUCLEOTIDE MIMICS AND THEIR PRODRUGS | BIOTA, INC. (US) | 2003-09-04 | — | — | WO | claimed |
| WO-2025072236-A1 | PUBLISHING DEVICE PUBLIC INFORMATION IN A WIRELESS BLOCKCHAIN SYSTEM | INTERDIGITAL PATENT HOLDINGS, INC. (US) | 2025-04-03 | — | — | WO | disclosed |
| CN-118295995-B | Multi-source geological data standardization processing method and system | 江西省地质博物馆 | 2024-08-13 | — | — | CN | disclosed |
| CN-118295995-A | Multi-source geological data standardization processing method and system | 江西省地质博物馆 | 2024-07-05 | — | — | CN | disclosed |
| US-11858953-B2 | Compositions and methods for synthesis of phosphorylated molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-01-02 | — | — | US | disclosed |
| CN-116842032-A | Commodity vector retrieval method and system based on contrast learning and commodity entity | 北京永辉科技有限公司 | 2023-10-03 | — | — | CN | disclosed |
| EP-2322518-B1 | Method of manufacture of 1,3-dioxolane and 1,3-oxathiolane nucleosides | GILEAD SCIENCES INC (US) | 2015-02-25 | — | — | EP | disclosed |
| EP-2509990-A1 | NOVEL PHOSPH(ON)ATE- AND SULF(ON)ATE-BASED PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL AGENTS | Katholieke Universiteit Leuven, K.U. Leuven R&D (BE) | 2012-10-17 | — | — | EP | disclosed |
| US-20030144532-A1 | Method of manufacture of 1,3-oxathiolane nucleosides | GILEAD SCIENCES, INC. | 2003-07-31 | — | — | US | disclosed |
| US-6576776-B1 | Method of manufacture of 1,3-oxathiolane nucleosides | TRIANGLE PHARMACEUTICALS, INC. | 2003-06-10 | — | — | US | disclosed |
| US-6566365-B1 | Administering a therapeutically effective amount of nucleoside analog compound for therapy of Flaviviridea viral infection in a host | BIOCHEM PHARMA INC. (CA) | 2003-05-20 | — | — | US | disclosed |
| US-6518425-B1 | A process for producing a 1,3-oxathiolane nucleoside comprising reacting a 5-halo-2-protected-oxymethyl-1,3-oxathiolane with a silylated purine or pyrimidine without the addition of a Lewis acid or an additional base to the reaction | EMORY UNIVERSITY | 2003-02-11 | — | — | US | disclosed |
| US-6350753-B1 | 2-ACETOXYMETHYL-4-(THYMIN-1'-YL)-1,3,-DIOXOLANE; 2-BENZOYLOXYMETHYL-4-(CYTOSIN-1'-YL)-1,3-DIOXOLANE; ANTIVIRAL AGENTS, PARTICULARY FOR THE TREATMENT OF THE HIV INFECTIONS IN MAMMALS, ESPECIALLY HUMANS | BIOCHEM PHARMA INC. (CA) | 2002-02-26 | — | — | US | disclosed |
| EP-1104415-A1 | METHOD OF MANUFACTURE OF 1,3-OXATHIOLANE NUCLEOSIDES | Triangle Pharmaceuticals Inc. (US) | 2001-06-06 | — | — | EP | disclosed |
| US-6215004-B1 | CYCLIZATION OF MERCAPTOACETIC ACID WITH ACETAL IN SOLVENT; SULFIDING | EMORY UNIVERSITY | 2001-04-10 | — | — | US | disclosed |
| WO-2000009494-A1 | METHOD OF MANUFACTURE OF 1,3-OXATHIOLANE NUCLEOSIDES | TRIANGLE PHARMACEUTICALS, INC. (US) | 2000-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259832-A1 | Nucleotide mimics and their prodrugs | NUDT14, ENTPD5, MTAP | POLA1 909/4885LMNA 3677/4885PDE3A 765/4885 |
| US-11858953-B2 | Compositions and methods for synthesis of phosphorylated molecules | PIK3CA, CHAMP1, TYMP | POLA1 198/4885LMNA 1794/4885PDE3A 2076/4885 |
| US-20030144532-A1 | Method of manufacture of 1,3-oxathiolane nucleosides | NUDT1, PNP, TYMP | POLA1 116/4885LMNA 989/4885PDE3A 637/4885 |
| US-20040059104-A1 | Nucleotide mimics and their prodrugs | NUDT14, ENTPD5, MTAP | POLA1 909/4885LMNA 3677/4885PDE3A 765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.